The CBR1 Knockout A-549 Polyclonal Cells product consists of a population of A-549 human lung adenocarcinoma epithelial cells that have undergone CRISPR/Cas9-mediated disruption of the CBR1 gene, generating a heterogeneous polyclonal knockout pool. This loss-of-function model enables the study of carbonyl reductase 1 in a relevant cellular context without enforcing clonal selection, preserving biological variability typical of tumor cell populations.
The parental A-549 cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male and is widely employed as a model of alveolar type II epithelium. These adherent epithelial cells retain key features of lung adenocarcinoma and are frequently utilized in cancer biology, drug metabolism, and toxicology investigations. The A-549 background provides a clinically pertinent platform for examining the role of CBR1 in anthracycline resistance and xenobiotic detoxification.
CBR1 encodes an NADPH-dependent carbonyl reductase that catalyzes the reduction of a broad spectrum of carbonyl substrates, including quinones, prostaglandins, and anthracycline chemotherapeutics such as daunorubicin. Its activity is regulated by the KEAP1-NFE2L2 (Nrf2) oxidative stress response pathway and the aryl hydrocarbon receptor (AHR), linking CBR1 expression to cellular redox status and electrophile exposure. Downstream, CBR1-mediated reduction inactivates prostaglandin E2 and converts anthracyclines to less cytotoxic secondary alcohol metabolites, thereby attenuating their anticancer efficacy. This enzyme functionally interacts with cytochrome P450 isoforms (e.g., CYP3A4) and aldo-keto reductases within phase I drug metabolism networks, positioning CBR1 at a critical node controlling both endogenous signaling molecule turnover and xenobiotic clearance.
In the A-549 lung adenocarcinoma context, knockout of CBR1 is predicted to heighten cellular sensitivity to carbonyl-bearing chemotherapeutic agents by preventing their metabolic inactivation, making this model valuable for dissecting mechanisms of anthracycline resistance. Aberrant CBR1 expression has been implicated in poor clinical response to doxorubicin and related compounds; thus, this polyclonal knockout pool provides a physiologically relevant system to evaluate how CBR1 loss reshapes drug susceptibility, redox balance, and prostaglandin-dependent inflammatory signaling. The model may also illuminate the interplay between CBR1 and NFE2L2-mediated adaptive responses in cancer cells.
This knockout cell population is suitable for a wide range of functional studies, including western blotting and RT-qPCR to confirm CBR1 ablation, MTT-based cytotoxicity assays with anthracyclines, measurement of prostaglandin E2 metabolites, and menadione-based activity assays to assess residual carbonyl reductase function. Transcriptomic profiling via RNA-seq can further characterize global gene expression changes resulting from CBR1 disruption. These cells additionally support co-treatment experiments with NFE2L2 inducers or AHR ligands to probe regulatory crosstalk. Researchers are encouraged to contact Ascent Research for additional details and technical support.
